Annarosa Finco

Mrs. Annarosa Finco

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2013 in Reproductive Biology and Endocrinology
Verified
Journal Article
Open access
PDF file
UCUmberto Cornelli
Umberto Cornelli
GBGianni Belcaro
Gianni Belcaro
MCMaria Rosaria Cesarone
Maria Rosaria Cesarone
AFAnnarosa Finco
Annarosa Finco
Background: Few data concerning the oxidative stress (OS) in plasma during the entire menstrual cycle of eumenorrheic women are available. Methods: OS was assessed in 20 healthy volunteers during the phase of the menstrual cycle by determining the plasmatic hydroperoxides levels (d-ROMs test). The assessment was performed every three days, starting from the first day (t1) up the end of the menstrual phase (t27). Concomitantly, the estrogen (E2) and progestin (P4) levels were determined at the same time intervals. Results: From a base value (t1) of 284 +/− 38.0 CARR.U., which is essentially within the normal range (300 CARR.U. Analysis of the E2 levels showed that the maximum OS values were noticed near the estrogen peak, while remaining above the base levels, and then decreased during the progestin phase until returning to normal at the end of the menstrual cycle. Conclusions: It may concludes that the healthy women go into OS for 2/3 of the menstrual cycle.

9 August 2020 in Aging Medicine
Verified
Journal Article
Open access
PDF file
DGDavide Gorni
Davide Gorni
AFAnnarosa Finco
Annarosa Finco
Background: Aging is a multifactorial phenomenon, characterized by a progressive decline in the efficiency of biochemical and physiological processes and an increased susceptibility to disease. There is increasing evidence that aging and age‐related disease are correlated with an oxidative stress (OS) condition. The latter is characterized by an imbalance between reactive species (RS), in particular reactive oxygen species (ROS) and antioxidant reserve.Objectives: The aim of this study is to evaluate the two main markers of oxidative stress, plasmatic peroxide concentration (through d‐ROMs FAST test, derivates‐Reactive Oxygen Metabolites) and plasmatic antioxidant power measured by iron‐reducing power (PAT test, Plasma Antioxidant Test) in 290 apparently healthy volunteers over 60, and their possible correlation with age and gender.Materials and methods: Human capillary blood samples from healthy volunteers were used in this observational study for the evaluation of the markers of OS.Results: The data obtained broadly demonstrate that the majority of elderly people display an OS condition characterized by increased levels of peroxides and a slight reduction in antioxidant reserve.Conclusions: Seniors have a greater propensity to develop a condition of oxidative stress, and therefore it is important to associate the monitoring of oxidative stress markers and, if necessary, antioxidant supplementation, with a healthy lifestyle.

8 August 2013 in Reproductive Biology and Endocrinology
Verified
Journal Article
Open access
PDF file
UCUmberto Cornelli
Umberto Cornelli
GBGianni Belcaro
Gianni Belcaro
MRMartino Recchia
Martino Recchia
AFAnnarosa Finco
Annarosa Finco
Background: Levothyroxine (LT4) treatment can lead to iatrogenic hyperthyroidism and oxidative stress that can cause patient discomfort. Oxidative stress is also recognized as one of the causes of chronic diseases and cancer. Methods: The prevalence of breast, colorectal, gastric and lung cancer in 18 Italian Regions during 2010 was correlated with the sales of LT4 in 2009. The cancer prevalence was analyzed in women aged 30–84. This age range corresponds to more than 80% of the consumers of the drug and to about 99% of all malignant cancers. The correlation between sales of LT4 and cancers was determined with the technique of Density Ellipses. The age and smoking contribution for lung cancer was determined with the Sequential test. Results: No significant correlation was seen between LT4 sales and breast, colorectal and gastric cancers. A significant correlation was instead found for lung cancer (p < 0.05) corrected for smoking and age. Conclusions: LT4 consumption in Italy is about 0.7 boxes/women/year. There is a correlation between lung cancer and LT4 treatment and oxidative stress caused by LT4 supplementation can be one of the causes. Although we cannot exclude that dysthyroidism needing LT4 supplementation might be the ground for lung cancer itself and measuring oxidative stress could be helpful in avoiding excessive use of the drug.

1 May 2012 in Contraception
Verified
Journal Article
Closed access
AFAnnarosa Finco
Annarosa Finco
GBGianni Belcaro
Gianni Belcaro
MCMaria Rosaria Cesarone
Maria Rosaria Cesarone

1 January 2013 in Clinical Laboratory
Verified
Journal Article
Closed access
SBSerena Benedetti
Serena Benedetti
MPMariangela Primiterra
Mariangela Primiterra
SCSimona Catalani
Simona Catalani
AFAnnarosa Finco
Annarosa Finco
FCFranco Canestrari
Franco Canestrari
UCUmberto Cornelli
Umberto Cornelli
Antioxidants (AOs) represent the main barrier of defense against damaging aggression due to reactive species, in particular by reactive oxygen species (ROS). The plasma AO capacity is a measure of physiological, environmental, and nutritional factors (exposure to ROS and antioxidant supplementation) determining the redox status in humans and can underline the oxidative stress (OS) conditions in the progression/development of many diseases. Moreover, changes in AO plasma content after supplementation may provide information on the absorption and bioavailability of nutritional compounds and efficacy of AO therapy. The aim of the study was a comparison between the common BAP (Biological Antioxidant Potential) test, used for the evaluation of the antioxidant capacity, and the innovative PAT (Plasma Antioxidant Test) and to assess both the in vitro interferences of phosphates on the iron reduction and the interference of the plasmatic concentration of phosphates in relation to the plasma antioxidant capacity measured with the two methods. Thirty-six apparently healthy volunteers were involved in the study for the comparison of the two methods. BAP test and PAT performed on 36 plasma samples demonstrated that plasma antioxidant capacity dosage using the BAP test resulted in overestimated levels in relation to plasma phosphate. Increased BAP values due to phosphates correspond to increased differences between BAP and PAT value (correlation coefficient R = 0.812, p = 0.001). PAT can be considered an innovative and predictable method for the measure of the antioxidant power of plasma.

17 April 2014 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
GBGianni Belcaro
Gianni Belcaro
UCUmberto Cornelli
Umberto Cornelli
AFAnnarosa Finco
Annarosa Finco
Despite the reduction in cholesterol (CH) levels, the modification of carotid intima–media thickness (CIMT) is not evident in all the patients treated with statins. Activities other than CH reduction may determine the improvement in CIMT. Twenty-two patients with hypercholesterolemia (aged 45-60; males) with CIMT increase started the treatment with atorvastatin. The CIMT (via echography), CH level, and the oxidative balance (OB) were measured at baseline and after 4 weeks. The OB consisted of the determination of the plasmatic hydroperoxides (reactive oxygen metabolites [d-ROMs] test) and the antioxidant reserve (plasma antioxidants test [PAT]). The d-ROMs/CH and PAT/CH ratios allowed to measure, respectively, the oxidative index (OI) and the protective index (PI). The OI/PI ratio represented the OB Risk Index (OBRI) to be compared with the CIMT modifications. An average reduction of 22% in CH was achieved in the group of patients together with an increase in both OI and PI (16% and 39% respectively) with a significant improvement in OBRI from 2.6 to 1.7 (analysis of variance P < .01). A reduction of >20% in CIMT was obtained in 10 patients whereas in the 12 patients no modification of CIMT was detected, despite the same CH reduction (−55 ± 24.8 and −66 ± 27.1 mg/dL respectively; P > .05). Only those patients with a decrease in OBRI ≥0.8 showed a reduction in CIMT >20%. In this preliminary study, a significant modification in CIMT was obtained with atorvastatin treatment only in those patients showing an improvement in the OB (OBRI > 0.8).